![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 58, Issue 3, 470-476, September 2000
-Independent Peroxisome Proliferation: Effects of
PPAR
/
-Specific Agonists in PPAR-Null Mice
Department of Molecular Endocrinology (T.W.D., L.J.K., S.P.S.,
J.V., M.S.W., D.E.M.), Merck Research Laboratories, Rahway, New Jersey;
Department of Safety Assessment/Genetic and Cellular Toxicology
(J.G.D., R.K.K., S.M.-N.), Merck Research Laboratories, West Point,
Pennsylvania; and Laboratory of Metabolism (J.M.P., F.J.G.), National
Cancer Institute, National Institutes of Health, Bethesda,
Maryland
Peroxisome proliferators are a diverse group of compounds that cause
hepatic hypertrophy and hyperplasia, increase peroxisome number, and on
chronic high-dose administration, lead to rodent liver tumorigenesis.
Various lines of evidence have led to the conclusion that these agents
induce their pleiotropic effects exclusively via agonism of peroxisome
proliferator-activated receptor (PPAR)
, a member of the
steroid receptor superfamily involved in the regulation of fatty acid
metabolism. Recently, agonists of two other members of this receptor
family have been identified. PPAR
is predominantly expressed in
adipocytes where it mediates differentiation; PPAR
is a widely
expressed orphan receptor with yet unresolved physiologic functions. In
the course of characterizing newer PPAR ligands, we noted that highly
selective PPAR agonists or dual PPAR/PPAR agonists, lacking
apparent murine PPAR agonist activity, cause
peroxisome proliferation in CD-1 mice. We therefore made use of PPAR
knockout mice to investigate whether these effects resulted from
agonism of PPAR by these agents at very high dose levels or whether
PPAR (or PPAR) agonism alone can result in peroxisome
proliferation. We report here that several parameters linked to the
hepatic peroxisome proliferation response in mice that were seen with
these agents resulted from PPAR-independent effects.
This article has been cited by other articles:
|
|
 |
|
  C. D. Kane, K. A. Stevens, J. E. Fischer, M. Haghpassand, L. J. Royer, C. Aldinger, K. T. Landschulz, P. Zagouras, S. W. Bagley, W. Hada, et al. Molecular Characterization of Novel and Selective Peroxisome Proliferator-Activated Receptor {alpha} Agonists with Robust Hypolipidemic Activity in Vivo Mol. Pharmacol., February 1, 2009; 75(2): 296 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Chess and W. C. Stanley Role of diet and fuel overabundance in the development and progression of heart failure Cardiovasc Res, July 15, 2008; 79(2): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Rosen, B. D. Abbott, D. C. Wolf, J. C. Corton, C. R. Wood, J. E. Schmid, K. P. Das, R. D. Zehr, E. T. Blair, and C. Lau Gene Profiling in the Livers of Wild-type and PPAR{alpha}-Null Mice Exposed to Perfluorooctanoic Acid Toxicol Pathol, June 1, 2008; 36(4): 592 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Rosen, J. S. Lee, H. Ren, B. Vallanat, J. Liu, M. P. Waalkes, B. D. Abbott, C. Lau, and J. C. Corton Toxicogenomic Dissection of the Perfluorooctanoic Acid Transcript Profile in Mouse Liver: Evidence for the Involvement of Nuclear Receptors PPAR{alpha} and CAR Toxicol. Sci., May 1, 2008; 103(1): 46 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Desvergne, L. Michalik, and W. Wahli Transcriptional Regulation of Metabolism Physiol Rev, April 1, 2006; 86(2): 465 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Anderson, P. Howroyd, J. Liu, X. Qian, R. Bahnemann, C. Swanson, M.-K. Kwak, T. W. Kensler, and J. C. Corton The Transcriptional Response to a Peroxisome Proliferator-activated Receptor {alpha} Agonist Includes Increased Expression of Proteome Maintenance Genes J. Biol. Chem., December 10, 2004; 279(50): 52390 - 52398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Huss and D. P. Kelly Nuclear Receptor Signaling and Cardiac Energetics Circ. Res., September 17, 2004; 95(6): 568 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Cattley Peroxisome Proliferators and Receptor-Mediated Hepatic Carcinogenesis Toxicol Pathol, February 1, 2004; 32(2_suppl): 6 - 11. [Abstract] [PDF]
|
|
|
|
|
|
E. B. E. Berry, R. Eykholt, R. J. A. Helliwell, R. S. Gilmour, M. D. Mitchell, and K. W. Marvin Peroxisome Proliferator-Activated Receptor Isoform Expression Changes in Human Gestational Tissues with Labor at Term Mol. Pharmacol., December 1, 2003; 64(6): 1586 - 1590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Gilde, K. A.J.M. van der Lee, P. H.M. Willemsen, G. Chinetti, F. R. van der Leij, G. J. van der Vusse, B. Staels, and M. van Bilsen Peroxisome Proliferator-Activated Receptor (PPAR) {alpha} and PPAR{beta}/{delta}, but not PPAR{gamma}, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism Circ. Res., March 21, 2003; 92(5): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Anderson, C. S. Dunn, R. C. Cattley, and J.C. Corton Hepatocellular proliferation in response to a peroxisome proliferator does not require TNF{alpha} signaling Carcinogenesis, November 1, 2001; 22(11): 1843 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cabrero, M. Alegret, R. M. Sanchez, T. Adzet, J. C. Laguna, and M. Vazquez Bezafibrate Reduces mRNA Levels of Adipocyte Markers and Increases Fatty Acid Oxidation in Primary Culture of Adipocytes Diabetes, August 1, 2001; 50(8): 1883 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-H. Hsu, U. Savas, K. J. Griffin, and E. F. Johnson Identification of Peroxisome Proliferator-responsive Human Genes by Elevated Expression of the Peroxisome Proliferator-activated Receptor alpha in HepG2 Cells J. Biol. Chem., July 20, 2001; 276(30): 27950 - 27958. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
